Clinical trials: Newly-diagnosed Cancers
Malignant Neoplasms of Brain
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone…
- Trial name
- ACTIVATe (NCT00643097)
- Testing
- PEP-3 vaccine, sargramostim, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- John Sampson
Ovarian Cancer, Ovarian Neoplasms
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07776691
- Testing
- R-DXd, Bevacizumab
- Where
- 11 sites in United States, Israel and 2 more
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Cancer
Head and Neck Cancer Registry (LORHAN)
The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient
- Trial name
- LORHAN (NCT01080313)
- Testing
- Therapy for head and neck cancer
- Where
- United States
- Volunteers
- 26,000 people
- Sponsor
- Eli Lilly and Company
Hodgkin Lymphoma, Adult
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
- Trial name
- NCT06984146
- Testing
- Nivolumab, Doxorubicin, Vinblastine
- Where
- Russia
- Volunteers
- 54 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
- Conditions
- Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Trial name
- QUATRO-APL (NCT07504458)
- Testing
- QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 150 people
- Sponsor
- Quetzal Therapeutics
Educational Activities
Parent Educational Discharge Support Strategies
After the initial hospitalization, parents of children newly diagnosed with cancer assume responsibility for assessing and managing their care; however, parents are often overwhelmed with information received throughout the…
- Trial name
- NCT03227068
- Testing
- PEDSS - symptom management, PEDSS - support for the caregiver
- Where
- 16 sites in United States, Saudi Arabia
- Volunteers
- 289 people
- Sponsor
- Duke University
Brain Tumor
Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors
Laser Interstitial Thermal Therapy (LITT) is a minimally invasive surgical technique that allows for biopsy and thermal ablation of brain tumors.
- Trial name
- NCT02451215
- Testing
- Laser Interstitial Thermotherapy (LITT)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
This was a clinical study for adult participants who were recently diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal.
- Trial name
- NCT02752035
- Testing
- gilteritinib, azacitidine
- Where
- 111 sites in United States, Australia and 11 more
- Volunteers
- 183 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) by itself (monotherapy) or in combination with other standard treatments.
- Trial name
- NCT02326584
- Testing
- Standard dose cytarabine for induction, SGN-CD33A, Daunorubicin
- Where
- 13 sites in United States
- Volunteers
- 116 people
- Sponsor
- Seagen Inc.
Multiple Myeloma
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
Lenalidomide is a standard of care for maintenance therapy after autologous stem cell transplantation in newly diagnosed myeloma patients.
- Trial name
- IFM 2024_06 (NCT06931704)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 36 sites in France
- Volunteers
- 176 people
- Sponsor
- Nantes University Hospital
Diffuse Intrinsic Pontine Glioma
Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma
The aim of the study is to determine the safety of Cilengitide in combination with radiation therapy.
- Trial name
- CILENT (NCT01165333)
- Testing
- Cilengitide dose escalation, Cilengitide, Concomitant radiotherapy
- Where
- 9 sites in France
- Volunteers
- 32 people
- Sponsor
- Centre Oscar Lambret
Leukemia
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.
- Trial name
- NCT01357655
- Testing
- Dasatinib, BMS-833923
- Where
- 24 sites in United States, Argentina and 6 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00006263
- Testing
- filgrastim, carboplatin, temozolomide
- Where
- United States
- Sponsor
- NYU Langone Health
Lymphoma
S8947-9800-9911-0016A Vitamin D Insufficiency in Determining Prognosis in Patients With Newly Diagnosed Follicular Lymphoma
RATIONALE: Studying samples of serum from patients with cancer in the laboratory may help doctors identify and learn more biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01131221
- Testing
- laboratory biomarker analysis
- Volunteers
- 196 people
- Sponsor
- SWOG Cancer Research Network
Oncology, Psychological Distress
Music Breathing for Caregivers of Children Newly Diagnosed With Cancer
This proposed pilot randomised controlled trial aims to examine the effect of mobile health-delivered music breathing therapy in enhancing resilience, reducing psychological distress and caregiver strain, and improving the coping…
- Trial name
- NCT06052904
- Testing
- mHealth-delivered music breathing therapy, Online educational modules
- Where
- Hong Kong
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
This phase I pilot trial studies the side effects of stereotactic radiosurgery and nivolumab in treating patients with newly diagnosed melanoma that has spread to the brain or spine.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine, Stage IV Skin Melanoma
- Trial name
- NCT02716948
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma (MM)
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
This is a multicenter, observational, retrospective-prospective study designed to validate the predictive role of advanced imaging in patients with newly diagnosed multiple myeloma (NDMM).
- Trial name
- NCT07746232
- Testing
- DW-MRI (MY-RADS/RAC score), Fat Fraction (rFF%), Clinical Data Collection
- Where
- 10 sites in Italy
- Volunteers
- 92 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade®…
- Trial name
- CLARION (NCT01818752)
- Testing
- Carfilzomib, Bortezomib, Melphalan
- Where
- 213 sites in United States, Argentina and 28 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Leukemia, Myeloid, Acute
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment naïve acute myeloid leukemia (AML) who are…
- Trial name
- NCT04241549
- Testing
- Cusatuzumab, Azacitidine
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- OncoVerity, Inc.
Brain and Central Nervous System Tumors
Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004200
- Testing
- prinomastat, temozolomide
- Where
- United States
- Sponsor
- Pfizer